Enzalutamide and Macitentan: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong CYP3A induction reduces macitentan exposure.
Clinical significance and safety
Enzalutamide and Macitentan: Opsumit product information advises avoiding strong CYP3A inducers because pulmonary-hypertension treatment may be less effective. A specialist should review alternatives and clinical response. Do not stop prescribed medicines yourself.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.